CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization, is collaborating with Xavier University on a new Master’s program that will fill jobs desperately needed in the health care industry.
The U.S. Bureau of Labor Statistics expects the demand for analysts to grow by 14% over the next 10 years, an increase of more than 2,300 jobs. The demand for health analysts in particular will likely outpace that projection.
To meet this demand, the Master of Science in Health Economic and Clinical Outcomes Research (HECOR) begins in Fall 2015. This 40-credit hour program is designed to train analysts to conduct both clinical and economic evaluations that support improved health decisions.
“The program that we have developed in partnership with Xavier is one of only a handful in the country,” said Dr. Candace Gunnarsson, Vice President of Health Economics & Outcomes Research at CTI and former faculty member at Xavier. “Students will study health economics, data mining, statistical modeling and epidemiology as they prepare for careers as analysts, managers and directors in the fast-growing field of health care analytics that includes outcomes research, policy, economics and reimbursement.”
Last year, CTI’s Consulting and HECOR divisions relocated to University Station, adjacent to the Xavier University campus. The company recently moved their Biometrics department to the location as well. When CTI identified a need to hire health economic and clinical outcome analysts, partnering with Xavier to provide the education necessary to fill those jobs was a natural fit.
“A rapidly changing landscape for the healthcare sector, driven in part by the 2010 Patient Protection and Affordable Care Act, combined with an aging population and medical force, as well as technological advancements within the industry make this program highly desirable,” said CTI CEO Tim Schroeder. “We are excited to extend our collaboration with Xavier University and look forward to developing the future HECOR leaders in this exciting and innovative research space.”
The 2 year, non-thesis program is designed to accommodate working professionals and people with a passion for solving problems using the latest health data to improve care. Courses are a combination of lectures, applied analysis exercises, group activities, discussion and case studies led by experienced full and part-time faculty who have practiced in the HECOR field, including CTI employees. Students complete a mentored capstone project during their final term.
Michael J. Graham, S.J., President of Xavier University, said the professional and community connection with CTI is critical to the program’s success. “The Jesuit education model will provide students the opportunity to explore ethical issues inherent in growing big data working in conjunction with an organization that is an industry leader in this important and growing field.”
Learn more about the degree at Xavier.edu/HECOR or contact Dr. Eileen Alexander directly at alexandere2@xavier.edu or 513-745-4957. Interviews for Fall 2015 admission are currently underway.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.